KR20220066922A - Parg 억제제로서 4-치환된 인돌 및 인다졸 설폰아미도 유도체 - Google Patents

Parg 억제제로서 4-치환된 인돌 및 인다졸 설폰아미도 유도체 Download PDF

Info

Publication number
KR20220066922A
KR20220066922A KR1020227012903A KR20227012903A KR20220066922A KR 20220066922 A KR20220066922 A KR 20220066922A KR 1020227012903 A KR1020227012903 A KR 1020227012903A KR 20227012903 A KR20227012903 A KR 20227012903A KR 20220066922 A KR20220066922 A KR 20220066922A
Authority
KR
South Korea
Prior art keywords
alkyl
hydrogen
heterocyclyl
compound
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227012903A
Other languages
English (en)
Korean (ko)
Inventor
주니어 제임스 클리포드 서튼
마이클 패트릭 딜런
Original Assignee
아이디어야 바이오사이언시스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아이디어야 바이오사이언시스 인코포레이티드 filed Critical 아이디어야 바이오사이언시스 인코포레이티드
Publication of KR20220066922A publication Critical patent/KR20220066922A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
KR1020227012903A 2019-09-20 2020-09-18 Parg 억제제로서 4-치환된 인돌 및 인다졸 설폰아미도 유도체 Pending KR20220066922A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962903438P 2019-09-20 2019-09-20
US62/903,438 2019-09-20
PCT/US2020/051486 WO2021055744A1 (en) 2019-09-20 2020-09-18 4-substituted indole and indazole sulfonamido derivatives as parg inhibitors

Publications (1)

Publication Number Publication Date
KR20220066922A true KR20220066922A (ko) 2022-05-24

Family

ID=72744866

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227012903A Pending KR20220066922A (ko) 2019-09-20 2020-09-18 Parg 억제제로서 4-치환된 인돌 및 인다졸 설폰아미도 유도체

Country Status (16)

Country Link
US (1) US20220389003A1 (cg-RX-API-DMAC7.html)
EP (1) EP4031249B1 (cg-RX-API-DMAC7.html)
JP (2) JP2022548690A (cg-RX-API-DMAC7.html)
KR (1) KR20220066922A (cg-RX-API-DMAC7.html)
CN (1) CN114555593A (cg-RX-API-DMAC7.html)
AU (1) AU2020348489B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022004624A2 (cg-RX-API-DMAC7.html)
CA (1) CA3147493A1 (cg-RX-API-DMAC7.html)
DK (1) DK4031249T3 (cg-RX-API-DMAC7.html)
FI (1) FI4031249T3 (cg-RX-API-DMAC7.html)
IL (1) IL291436B1 (cg-RX-API-DMAC7.html)
LT (1) LT4031249T (cg-RX-API-DMAC7.html)
MX (1) MX2022003276A (cg-RX-API-DMAC7.html)
PT (1) PT4031249T (cg-RX-API-DMAC7.html)
TW (1) TWI873187B (cg-RX-API-DMAC7.html)
WO (1) WO2021055744A1 (cg-RX-API-DMAC7.html)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41179A (fr) 2014-12-19 2017-10-24 Cancer Research Tech Ltd Composés inhibiteurs de parg
US20250002491A1 (en) 2021-10-04 2025-01-02 Forx Therapeutics Ag N,n-dimethyl-4-(7-(n-(1-methylcyclopropyl)sulfamoyl)-imidazo[1,5-a]pyridin-5-yl)piperazine-1-carboxamide derivatives and the corresponding pyrazolo[1,5-a]pyridine derivatives as parg inhibitors for the treatment of cancer
CA3225500A1 (en) 2021-10-04 2023-04-13 Ulrich Luecking Parg inhibitory compounds
IL311851A (en) * 2021-10-04 2024-05-01 Forx Therapeutics Ag PARG inhibitory compounds
CA3251360A1 (en) 2022-02-14 2023-08-17 Arase Therapeutics Inc. PARG INHIBITORS
EP4488275A4 (en) * 2022-03-04 2025-07-23 Shanghai Yingli Pharm Co Ltd COMPOUND CONTAINING A FIVE-MEMBERED HETEROAROMATIC RING STRUCTURE, PHARMACEUTICAL COMPOSITION AND USE THEREOF
WO2023175184A1 (en) 2022-03-17 2023-09-21 Forx Therapeutics Ag 2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer
WO2023175185A1 (en) 2022-03-17 2023-09-21 Forx Therapeutics Ag 2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer
PL4496795T3 (pl) * 2022-03-23 2026-07-20 Ideaya Biosciences, Inc. Związki indazolowe podstawione piperazyną jako inhibitory parg
IL316261A (en) 2022-04-28 2024-12-01 Danatlas Pharmaceuticals Co Ltd Tricyclic and heterocyclic derivatives, preparations and uses thereof
TW202409036A (zh) 2022-05-17 2024-03-01 美商858療法股份有限公司 Parg抑制劑
TWI878939B (zh) * 2022-06-29 2025-04-01 大陸商杭州聖域生物醫藥科技有限公司 五元並六元含氮化物、其中間體、製備方法和應用
AU2023310489A1 (en) * 2022-07-19 2025-02-13 Evopoint Biosciences Co., Ltd. Sulfur-containing heteroaromatic ring compound, pharmaceutical composition thereof, and use thereof
EP4311829A1 (en) 2022-07-28 2024-01-31 Nodus Oncology Limited Substituted bicyclic heteroaryl sulfonamide derivatives for the treatment of cancer
IL320031A (en) 2022-10-03 2025-06-01 Forx Therapeutics Ag Parg inhibitory compound
CN120051465A (zh) * 2022-10-13 2025-05-27 韩美药品株式会社 用于抑制yap-tead交互作用的新颖杂双环化合物及包含其的药学组成物
EP4646208A1 (en) 2023-01-06 2025-11-12 Ideaya Biosciences, Inc. Treatment of er+ breast cancer comprising homologous recombination deficiency using parg inhibitor
WO2024173234A1 (en) * 2023-02-13 2024-08-22 Arase Therapeutics Inc. Inhibitors of parg
WO2024173530A1 (en) * 2023-02-14 2024-08-22 Ideaya Biosciences, Inc. Heteroaryl-substituted pyrazolo/imidazo pyridine compounds
WO2024173524A1 (en) * 2023-02-14 2024-08-22 Ideaya Biosciences, Inc. Heteroaryl-substituted benzimidazole compounds
WO2024173453A1 (en) * 2023-02-14 2024-08-22 Ideaya Biosciences, Inc. Heteroaryl-substituted imidazopyridine compounds
WO2024173514A1 (en) * 2023-02-14 2024-08-22 Ideaya Biosciences, Inc. Amide and ester-substituted imidazopyridine compounds
WO2024209035A1 (en) 2023-04-05 2024-10-10 Forx Therapeutics Ag Parg inhibitory compounds
AU2024253809A1 (en) 2023-04-05 2025-10-16 Ideaya Biosciences, Inc. Combination therapy comprising a parg inhibitor and a topoisomerase inhibitor for treating cancer
CN121002021A (zh) * 2023-04-27 2025-11-21 北京丹擎医药科技有限公司 三环杂环衍生物及其组合物和应用
WO2024254990A1 (zh) 2023-06-16 2024-12-19 上海璎黎药业有限公司 一种杂芳环结构化合物、其药物组合物及应用
WO2025046148A1 (en) 2023-09-01 2025-03-06 Forx Therapeutics Ag Novel parg inhibitors
WO2025064750A1 (en) 2023-09-20 2025-03-27 Ideaya Biosciences, Inc. Combination therapy with a parg inhibitor
TW202528308A (zh) * 2023-09-20 2025-07-16 美商愛德亞生物科學公司 Parg抑制劑
WO2025072544A1 (en) * 2023-09-27 2025-04-03 Ideaya Biosciences, Inc. Sulfonamino indazole compounds as inhibitors of parg
WO2025067464A1 (zh) * 2023-09-28 2025-04-03 杭州圣域生物医药科技有限公司 杂芳基化合物、其中间体、制备方法和应用
KR20260084620A (ko) 2023-10-03 2026-06-05 포알엑스 테라퓨틱스 아게 Parg 억제 화합물
WO2025082231A1 (zh) * 2023-10-20 2025-04-24 上海璎黎药业有限公司 一种杂芳环磺酰胺结构化合物、其药物组合物及应用
WO2025087941A1 (en) 2023-10-23 2025-05-01 Universite De Geneve Parg inhibitors in combination with parp inhibitors and uses thereof
CN122249439A (zh) 2023-10-26 2026-06-19 上海齐鲁制药研究中心有限公司 Parg抑制剂
WO2025087274A1 (zh) 2023-10-27 2025-05-01 浙江海正药业股份有限公司 氮杂双环类衍生物及其制备方法和用途
WO2025093755A1 (en) 2023-11-01 2025-05-08 Forx Therapeutics Ag Novel parc inhibitors
WO2025098445A1 (zh) * 2023-11-07 2025-05-15 南京同诺康医药科技有限公司 Parg抑制剂及其制备方法和用途
WO2025108225A1 (zh) * 2023-11-20 2025-05-30 上海复星医药(集团)股份有限公司 作为parg抑制剂的含氮三环衍生物
WO2025111339A1 (en) * 2023-11-21 2025-05-30 858 Therapeutics, Inc. Treatment of cancer with a parg inhibitor
AR134429A1 (es) * 2023-11-22 2026-01-14 858 Therapeutics Inc Inhibidores de parg
WO2025133396A1 (en) 2023-12-22 2025-06-26 Forx Therapeutics Ag Novel bicyclo heteroaryl parg inhibitors
WO2025133191A1 (en) * 2023-12-22 2025-06-26 Genecode Novel sulfonamides or sulfones and their use as neuroprotective and/or neurorestorative agents
WO2025229549A1 (en) * 2024-04-30 2025-11-06 Satyarx Pharma Innovations Pvt Ltd Novel heterocyclic compounds as inhibitors of parg
CN118459452B (zh) * 2024-07-10 2024-10-25 苏州国匡医药科技有限公司 一种多聚adp核糖水解酶抑制剂及其应用
WO2026022150A1 (en) 2024-07-22 2026-01-29 Forx Therapeutics Ag Parg inhibitory compounds
TW202610628A (zh) * 2024-07-29 2026-03-16 大陸商海思科醫藥集團股份有限公司 磺醯胺化合物及其在醫藥上的應用
WO2026032385A1 (zh) * 2024-08-07 2026-02-12 上海亚虹医药科技有限公司 多聚adp核糖水解酶抑制剂及其医药用途
WO2026040953A1 (zh) * 2024-08-19 2026-02-26 上海和誉生物医药科技有限公司 一种多环parg抑制剂和其应用
WO2026042050A1 (en) * 2024-08-23 2026-02-26 Recursion Pharmaceuticals, Inc. Novel compounds and uses thereof
WO2026060261A1 (en) * 2024-09-13 2026-03-19 Equator Therapeutics, Inc. Compositions and methods for treating metabolic disorders
WO2026062066A1 (en) 2024-09-17 2026-03-26 Forx Therapeutics Ag Compounds inducing parg degradation

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
CA2242425C (en) 1996-02-13 2006-07-18 Zeneca Limited Quinazoline derivatives as vegf inhibitors
NZ331191A (en) 1996-03-05 2000-03-27 Zeneca Ltd 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
EE05345B1 (et) 1999-02-10 2010-10-15 Astrazeneca Ab Kinasoliini derivaadid angiogeneesi inhibiitoritena
BR0111230A (pt) 2000-05-31 2003-06-10 Astrazeneca Ab Composto, e, uso e processo para a preparação do mesmo
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
KR20030014425A (ko) 2000-07-07 2003-02-17 앤지오젠 파마슈티칼스 리미티드 혈관 손상제인 콜치놀 유도체
EE200300015A (et) 2000-07-07 2004-10-15 Angiogene Pharmaceuticals Limited Kolhinooli derivaadid kui angiogeneesi inhibiitorid
CA2834101A1 (en) * 2011-01-07 2012-07-12 Taiho Pharmaceutical Co., Ltd. Novel indole or indazole derivative or salt thereof
MA41140A (fr) * 2014-12-12 2017-10-17 Cancer Research Tech Ltd Dérivés de 2,4-dioxo-quinazoline-6-sulfonamide en tant qu'inhibiteurs de la parg
MA41179A (fr) * 2014-12-19 2017-10-24 Cancer Research Tech Ltd Composés inhibiteurs de parg
AU2018352695A1 (en) * 2017-10-19 2020-05-28 Effector Therapeutics, Inc. Benzimidazole-indole inhibitors of Mnk1 and Mnk2
PT3870575T (pt) * 2018-10-25 2023-05-12 Viiv Healthcare Uk No 5 Ltd Inibidores da replicação do vírus da imunodeficiência humana
PL4496795T3 (pl) * 2022-03-23 2026-07-20 Ideaya Biosciences, Inc. Związki indazolowe podstawione piperazyną jako inhibitory parg

Also Published As

Publication number Publication date
CN114555593A (zh) 2022-05-27
AU2020348489B2 (en) 2026-06-25
JP7781244B2 (ja) 2025-12-05
JP2025016684A (ja) 2025-02-04
BR112022004624A2 (pt) 2022-05-31
MX2022003276A (es) 2022-04-11
LT4031249T (lt) 2026-08-10
WO2021055744A1 (en) 2021-03-25
PT4031249T (pt) 2026-07-16
DK4031249T3 (da) 2026-07-27
JP2022548690A (ja) 2022-11-21
TWI873187B (zh) 2025-02-21
CA3147493A1 (en) 2021-03-25
IL291436A (en) 2022-05-01
US20220389003A1 (en) 2022-12-08
FI4031249T3 (fi) 2026-07-23
IL291436B1 (en) 2026-07-01
EP4031249A1 (en) 2022-07-27
AU2020348489A1 (en) 2022-05-05
EP4031249B1 (en) 2026-06-17
TW202120501A (zh) 2021-06-01

Similar Documents

Publication Publication Date Title
JP7781244B2 (ja) Parg阻害剤としての4-置換インドールおよびインダゾールスルホンアミド誘導体
EP3630749B1 (en) 2-quinolone derived inhibitors of bcl6
KR102616970B1 (ko) Prmt5-매개성 질환의 치료 또는 예방에 유용한 화합물
CA2976741C (en) 1-cyano-pyrrolidine compounds as usp30 inhibitors
JP7493454B2 (ja) Bcl6阻害剤
CA3225500A1 (en) Parg inhibitory compounds
WO2018167276A1 (en) Tricyclic compounds for use in treatment of proliferative disorders
BR112015004489B1 (pt) Composto, composição farmacêutica, e, uso de um composto
WO2019089835A1 (en) Diazanaphthalen-3-yl carboxamides and preparation and use thereof
WO2024173453A1 (en) Heteroaryl-substituted imidazopyridine compounds
WO2024173524A1 (en) Heteroaryl-substituted benzimidazole compounds
JP2024508547A (ja) ベンゾ[c][2,6]ナフチリジン誘導体、組成物およびその治療的使用
WO2024173514A1 (en) Amide and ester-substituted imidazopyridine compounds
WO2023175185A1 (en) 2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer
EP3481824A1 (en) 2-phenylimidazo[4,5-b]pyridin-7-amine derivates useful as inhibitors of mammalian tyrosine kinase ror1 activity
CN120858100A (zh) 抑制性化合物
WO2024052702A1 (en) Novel compounds as ck2 inhibitors
US20260070901A1 (en) Novel compounds as ck2 inhibitors
EP4413001A1 (en) Parg inhibitory compounds

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000